antigen

Syk inhibitor II, a cell-permeable, ATP-competitive, pyrimidine-carboxamide compound, selectively and reversibly inhibits Syk (IC50 = 41 nM).

3,29-O-Dibenzoyloxykarounidiol is a natural product with regulate blood sugar level, has potent inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) induced by tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA).

The nucleocapsid of the hepatitis B virus is covered by an envelope of HBV surface antigen (HBsAg), which has the common, group-specific determinant a. The four major subtypes of HBsAg, adw, adr, ayw and ayr, are generated, and they have been proposed to

MAGE-3 Antigen (167-176) (human) is an eight-amino-acid polypeptide epitope for HLA-B44 molecules, encoded by the melanoma antigen gene (MAGE) [1].

Blood group A antigen tetraose type 5 (A-Tetrasaccharide), a tetrasaccharide specific to blood group A, inhibits the binding of anti-A antibody to blood group A substance and can be isolated from polar bear milk samples [1] [2].

Carcinoembryonic antigen peptide 1 (CEA peptide) is a Carcinoembryonic Antigen (CEA) derived peptide, of which sequen is YLSGANLNL. CEA is a broad-spectrum tumour marker, a glycoprotein produced by colorectal cancer tissues, which acts as an antigen to elicit an immune response.

SV40 large T antigen NLS, originating from Large T antigen residue 47 to 55, facilitates protein import into the cell nucleus. This peptide is specifically generated from Large T antigen residue 47 to 55.

SV40 large T antigen NLS acetate is from Large T antigen residue 47 to 55, enables protein import into cell nucleus.

Large T antigen - rhesus polyomavirus 560-568 has a peptide sequence of Ser-Glu-Phe-Leu-Leu-Glu-Lys-Arg-Ile. T antigen is required for viral DNA replication, transcription, and virion assembly.

MHC class II antigen (45-57) [Homo sapiens] is a peptide with the sequence H2N-Asp-Leu-Asp-Lys-Lys-Glu-Thr-Val-Trp-His-Leu-Glu- Glu-OH, MW= 1868.07. MHC (major histocompatibility complex) class II molecules are found only on antigen-presenting cells and l

MART-1 nonamer antigen (LAGIGILTV) is a melanoma antigen recognizable by T cells. It functions as a superagonist by enhancing the immunological response of specific T cells when induced ex vivo. Additionally, MART-1 nonamer antigen serves as a peptide model for designing antitumor vaccines.

Mage-1 Antigen (161-169), human is a polypeptide molecule with the sequence EADPTGHSY.

Prostate specific antigen protein (human) is a serine protease produced by the prostate epithelium. It is utilized in prostate cancer research.

SSA antigenic peptide represents the antigenic fragment associated with Sjögren's syndrome-related antigen A (SSA) [1].

Sorafenib (Bay 43-9006) is a multikinase inhibitor that targets Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6 22 90 15 20 20 57 58 nM) with oral activity. It exhibits antitumor properties and can induce autophagy, apoptosis, and agonistic iron death.

Lipopolysaccharides (LPS) derived from Escherichia coli 055:B5, are a unique component of the cell wall of Gram-negative bacteria. They are composed of three regions: lipid A, oligosaccharide core, and O-specific polysaccharide (O-antigen). Lipopolysaccharides help maintain the integrity of the cell outer membrane and protect bacteria from damage by bile salts and lipid antibiotics. Lipopolysaccharides are highly immunogenic antigens that can enhance immune responses and can be used to construct inflammatory models.

Quizartinib (AC220) is an inhibitor of FLT3 (Kd: 1.6 nM) and demonstrates high selectivity for FLT3 when tested against a panel of 227 additional kinases.

Datopotamab deruxtecan (DS-1062) is a trophoblast cell surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC) with antitumor activity. Datopotamab deruxtecan induces significant antibody-dependent cellular cytotoxicity in the presence of peripheral blood lymphocytes and inhibits tumor growth in xenograft models.

Gilteritinib (ASP2215) is a potent inhibitor of FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preclinical studies, gilteritinib demonstrated strong antileukemic and antitumor effects. Gilteritinib is currently in several Phase 3 clinical trials for acute myeloid leukemia.

Fostamatinib (R788)(IC50 of 41 nM), which is a prodrug of the active metabolite R406, is a Syk inhibitor. It does not work on Lyn.

AOH1996 is an orally active ligand for the replicasome component PCNA (proliferating cell nuclear antigen), targeting the transcription-replication conflict (TRC). It interferes with the interaction of PCNA with its binding proteins, leading to DNA replication stress and apoptosis. AOH1996 causes proteasome-dependent rpb1 degradation and lethal DNA damage by stabilizing the interaction between PCNA and RNA polymerase II, and acts synergistically with DNA damaging agents to inhibit tumor cell growth.

Ripretinib (DCC-2618) is an orally bioavailable inhibitor of (KIT) and (PDGFRA).

AOH1160 is an inhibitor of proliferating cell nuclear antigen (PCNA). AOH1160 induces apoptosis and causes cell-cycle arrest by interfering with DNA replication.

RS-601 is a potent dual leukotriene D4 thromboxane A2 inhibitor that inhibits antigen-induced airway hyperresponsiveness (AHR) and shows asthmatic effects in a guinea pig model of asthma.